SLC3A2

Across TCGA pan-cancer cohorts, SLC3A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC3A2 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SLC3A2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC3A2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, PDAC, and LUAD are the cancer types where SLC3A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.922	0.681	.004	15	view →
PDAC	DFS	Quartile	All	0.216	0.538	<.001	14	view →
LUAD	DFS	Quartile	III,IV	0.953	0.264	.006	12	view →
HNSC	DFS	Median	All	0.996	0.906	.005	11	view →
CCRCC	DFS	Median	II,III,IV	0.451	1.000	.008	11	view →
LSCC	DFS	Median	All	0.800	0.612	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC3A2–GBM (DFS)

Open the GBM breakdown →